Publications

Search or filter publications

Search publications Search

Filter by type:

Filter by publication type

• Book
• Book chapter
• Conference paper
• Journal article
• Other
• Patent
• Poster
• Report
• Scholarly edition
• Software
• Thesis dissertation
• Working paper

Filter by year:

Filter from 20262025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980 to Filter to 20262025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980

---

Search results

• Journal article
  Goodwin GM, Aaronson ST, Alvarez O, Carhart-Harris R, Chai-Rees J, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Kirlic N, Licht RW, Marwood L, Meyer TD, Mistry S, Nowakowska A, Páleníček T, Repantis D, Schoevers RA, Simmons H, Somers M, Teoh E, Tsai J, Wahba M, Williams S, Young AH, Young MB, Zisook S, Malievskaia Eet al., 2026,

  Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].

  , J Affect Disord, Vol: 393
  • Author Web Link
  • Cite
• Journal article
  Zafar R, 2025,

  High hopes? Precision psychedelic addiction medicine

  , Frontiers in Psychiatry, ISSN: 1664-0640

  Despite decades of neuroscience research and significant investment in addiction neuroimaging, clinical outcomes for individuals with substance use and behavioural addictions remain poor. Only 1.8% of people with substance use disorders receive effective treatment, highlighting a major disconnect between mechanistic understanding and clinical utility. This paper calls for a reorientation of addiction neuroscience, from a predominantly diagnostic focus toward a theragnostic framework, in which biomarkers are used to stratify patients, guide treatment decisions, and predict outcomes. We argue that the integration of translational neuroimaging biomarkers, particularly fMRI, EEG, and PET, within psychedelic addiction research offers a unique and timely opportunity to catalyse this shift. Psychedelic compounds such as psilocybin represent a new class of therapeutics capable of engaging neuroplasticity, reward and emotional processing, and cognitive control networks central to addiction pathophysiology. We review how acute and pre– post neuroimaging paradigms can index pharmacodynamic effects and longer-term treatment response and propose a roadmap for embedding biomarkers in early and late phase clinical trials. Drawing on ongoing studies at the Centre for Psychedelic Research at Imperial College London, we outline how multimodal biomarkers are being co-developed alongside clinical trials in gambling and opioid use disorders to identify biotype-specific responses and build a deeply phenotyped treatment population. We argue that these biomarkers, if validated, could serve as regulatory-grade tools for drug theragnostic co-development, mirroring successful models in oncology and 2 neurology. Importantly, we emphasise that realising this vision will require robust multi-stakeholder collaboration, including academia, industry, regulatory agencies, funders, healthcare systems, and patient groups alongside dedicated investment to build a scalable theragnostic infrastruct

  • Abstract
  • Publisher Web Link
  • Cite
• Journal article
  Nutt DJ, 2025,

  Farewell to Jim Watson (and Francis Crick). A reflection on their contributions to psychiatry and brain science.

  , J Psychopharmacol
  • Author Web Link
  • Cite
• Journal article
  Nutt DJ, 2025,

  Obituary: Jan K. Melichar, BSc, MB, BS, MD, FRCPsych

  , BJPSYCH BULLETIN, ISSN: 2056-4694
  • Cite
• Journal article
  Hojlund M, Kafali HY, Kirmizi B, Fusar-Poli P, Correll CU, Cortese S, Sabe M, Fiedorowicz J, Saraf G, Zein J, Berk M, Husain MI, Rosenblat JD, Rubaiyat R, Corace K, Wong S, Hatcher S, Kaluzienski M, Yatham LN, Cipriani A, Gosling CJ, Carhart-Harris R, Tanuseputro P, Myran DT, Fabiano N, Moher D, Mayo LM, Nicholls SG, White T, De Prisco M, Radua J, Vieta E, Ladha KS, Katz J, Veroniki AA, Solmi Met al., 2025,

  Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis

  , EUROPEAN NEUROPSYCHOPHARMACOLOGY, Vol: 101, Pages: 41-55, ISSN: 0924-977X
  • Cite
• Journal article
  Bailey NW, Hill AT, Godfrey K, Perera MPN, Rogasch NC, Fitzgibbon BM, Fitzgerald PBet al., 2025,

  EEG is better when cleaning effectively targets artifacts

  , CLINICAL NEUROPHYSIOLOGY, Vol: 180, ISSN: 1388-2457
  • Cite
  • Citations: 1
• Journal article
  Purple RJ, Gupta R, Thomas CW, Golden CT, Palomero-Gallagher N, Carhart-Harris R, Froudist-Walsh S, Jones MWet al., 2025,

  Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin (AUG, 10.1038/s41380-025-03182-y, 2025)

  , MOLECULAR PSYCHIATRY, Vol: 30, Pages: 6172-6172, ISSN: 1359-4184
  • Cite
• Journal article
  Irrmischer M, Aqil M, Luan L, Wang T, Engelbregt H, Carhart-Harris R, Linkenkaer-Hansen K, Timmermann Cet al., 2025,

  DMT-induced shifts in criticality correlate with self-dissolution.

  , J Neurosci

  Psychedelics profoundly alter subjective experience and brain dynamics. Brain oscillations express signatures of near-critical dynamics, relevant for healthy function. Alterations in the proximity to criticality have been suggested to underlie the experiential and neurological effects of psychedelics. Here, we investigate the effects of a psychedelic substance (DMT) on the criticality of brain oscillations, and in relation to subjective experience, in humans of either sex. We find that DMT shifts the dynamics of brain oscillations away from criticality in alpha and adjacent frequency bands. In this context, entropy is increased while complexity is reduced. We find that the criticality shifts observed in alpha and theta bands correlate with the intensity ratings of self-dissolution, a hallmark of psychedelic experience. Finally, using a recently developed metric, the functional excitatory-inhibitory ratio, we find that the DMT-induced criticality shift in brain oscillations is towards subcritical regimes. These findings have major implications for the understanding of psychedelic mechanisms of action in the human brain and for the neurological basis of altered states of consciousness.Significance statement Criticality is characterized by fluctuations occurring on a wide range of spatiotemporal scales and high complexity. Here, we investigate the effects of DMT, a classic psychedelic, on criticality of brain oscillations and in relation to subjective experience. We find that DMT shifts the normally dominant alpha oscillations towards a quieter subcritical state, increasing entropy while reducing complexity, and that this shift correlates with intensity of disruption of the sense of self.

  • Abstract
  • Author Web Link
  • Cite
• Journal article
  Alnagger NLN, Cardone P, Martial C, Perl YS, Mindlin I, Sitt JD, Roseman L, Carhart-harris R, Nutt D, Mallaroni P, Mason N, Ramaekers JG, Bonhomme V, Laureys S, Deco G, Gosseries O, Nunez P, Annen Jet al., 2025,

  A Virtual Clinical Trial of Psychedelics to Treat Patients With Disorders of Consciousness

  , ADVANCED SCIENCE
  • Cite
• Journal article
  Martens MAG, Cunha BG, Erritzoe D, Nutt D, Carhart-Harris R, Harmer CJet al., 2025,

  Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial

  , TRANSLATIONAL PSYCHIATRY, Vol: 15, ISSN: 2158-3188
  • Cite

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.